Pier Capital’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Pier Capital’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-36,491	Closed	-$4.33M	–	112
2022 Q1	$4.33M	Sell	36,491 -49,411	-58%	-$6.16M	0.55%	85
2021 Q4	$11.8M	Sell	85,902 -1,311	-2%	-$167K	1.25%	27
2021 Q3	$12.1M	Sell	87,213 -26,705	-23%	-$3.33M	1.26%	22
2021 Q2	$11.1M	Sell	113,918 -49,016	-30%	-$3.98M	1.11%	41
2021 Q1	$11.1M	Buy	162,934 +96,322	+145%	+$7.79M	1.06%	54
2020 Q4	$5.71M	Buy	66,612 +2,117	+3%	+$179K	0.6%	90
2020 Q3	$4.19M	Sell	64,495 -813	-1%	-$53.3K	0.61%	91
2020 Q2	$4.78M	Sell	65,308 -36,726	-36%	-$1.95M	0.76%	80
2020 Q1	$3.47M	Buy	102,034 +35,135	+53%	+$1.61M	0.77%	68
2019 Q4	$3.64M	Sell	66,899 -42,026	-39%	-$2.08M	0.6%	87
2019 Q3	$4.54M	Sell	108,925 -4,650	-4%	-$196K	0.77%	74
2019 Q2	$4.97M	Buy	113,575 +44,786	+65%	+$2.52M	0.77%	78
2019 Q1	$3.54M	Buy	+68,789	New	+$2.97M	0.55%	92

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pier Capital's BHVN Position: Q2 2022 in Review

Pier Capital sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 36,491 shares — an estimated $4.33M sold.

Pier Capital first reported a position in BHVN in Q1 2019 and held it in 13 quarters. The position peaked at $12.1M in Q3 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Pier Capital reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Pier Capital sold 36,491 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $4.33M.
Pier Capital first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 13 quarters.
Pier Capital's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $12.1M in Q3 2021.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Pier Capital's 13F filing for Q2 2022, filed 15 Aug 2022.